Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 352,300 shares, a growth of 20.8% from the February 28th total of 291,600 shares. Based on an average daily trading volume, of 141,900 shares, the days-to-cover ratio is currently 2.5 days. Currently, 0.6% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NAUT. The Goldman Sachs Group downgraded Nautilus Biotechnology from a “neutral” rating to a “sell” rating and reduced their price objective for the stock from $2.25 to $1.75 in a research report on Thursday, December 5th. Guggenheim set a $2.50 target price on shares of Nautilus Biotechnology in a research report on Friday, February 28th.

Nautilus Biotechnology Trading Down 6.4 %

Nautilus Biotechnology stock opened at $0.78 on Thursday. The firm has a market capitalization of $98.02 million, a P/E ratio of -1.52 and a beta of 1.25. The business has a 50-day moving average of $1.37 and a 200-day moving average of $2.01. Nautilus Biotechnology has a 1 year low of $0.78 and a 1 year high of $3.09.

Insider Buying and Selling at Nautilus Biotechnology

In related news, CEO Sujal M. Patel acquired 53,300 shares of the stock in a transaction dated Wednesday, March 19th. The shares were acquired at an average price of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the purchase, the chief executive officer now owns 10,117,788 shares in the company, valued at approximately $10,016,610.12. The trade was a 0.53 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 40.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Nautilus Biotechnology in the fourth quarter worth $28,000. Cubist Systematic Strategies LLC bought a new stake in shares of Nautilus Biotechnology in the fourth quarter worth about $34,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Nautilus Biotechnology during the third quarter worth about $67,000. Squarepoint Ops LLC bought a new position in shares of Nautilus Biotechnology during the 4th quarter valued at about $44,000. Finally, SG Americas Securities LLC grew its position in shares of Nautilus Biotechnology by 56.3% in the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock valued at $46,000 after purchasing an additional 9,904 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.